Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Head Neck. 2019 Feb;41(2):403-410. doi: 10.1002/hed.25460. Epub 2018 Dec 12.

Evaluation of the theranostic properties of gadolinium-based nanoparticles for head and neck cancer.

Author information

1
Cancer Target and Experimental Therapeutics, Institute for Advanced Biosciences, INSERM U1209, CNRS UMR5309, Univ. Grenoble Alpes, Grenoble, France.
2
Department of Otolaryngology-Head and Neck Surgery, Grenoble Alpes University Hospital, Grenoble, France.
3
Institut Lumière Matière, CNRS UMR 5306, Université ć Claude Bernard, Lyon, France.
4
NHTheraguix, Crolles, France.

Abstract

BACKGROUND:

The aim of the study was to evaluate the benefits of the combination of Gadolinium-based nanoparticles AGuIX and radiotherapy on the recurrence free survival after tumor resection in a head and neck animal orthotopic model.

METHODS:

Human head and neck CAL33 orthotopic tumors were implanted in female NMRI nude mice. The biodistribution of AGuIX was studied by fluorescence imaging. Tumor resection was performed 19 days after tumor implantation. Radiotherapy was performed 23 days after resection (10 Gy), 1 hour after AGuIX IV injection.

RESULTS:

After systemic administration, AGuIX passively accumulated in the orthotopic tumors. After tumor surgery, the combination of AGuIX with radiotherapy significantly improved the recurrence free survival and the median survival time (196 days) compared to irradiated only mice (75 days).

CONCLUSION:

This study demonstrated the improvement of the recurrence free survival following combination of AGuIX injection with radiotherapy after Head and neck tumor resection.

KEYWORDS:

gadolinium; head and neck cancer; nanoparticles; orthotopic animal model; radiotherapy

PMID:
30548507
DOI:
10.1002/hed.25460

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center